How the microbiome affects the immune system
The building blocks of life-long health are the subject of a cutting-edge review examining how a newborn’s lung microbiome affects the immune system for years to come.
This interdisciplinary team brings together paediatricians, immunologists and experts in microbiota and systems biology to review and discuss how early life colonisation and community changes in the lung correlate with immune development and health and disease throughout infancy, childhood, and adult life.
Their analysis, published recently in the journal Science Translational Medicine, looks at how the colonisation of the lungs in newborns can impact the development of the growing immune system and therefore the future health of the individual.
“Colonisation of the lungs” refers to the process during birth and in the earliest days of life when microorganisms from the outside environment make their way into the baby’s airways.
Considering immune system and microbiome together
Professors Claudia and Marcel Nold from Hudson Institute of Medical Research, Monash University’s Department of Paediatrics and Monash Health believe it’s an important first step in an increasingly relevant field of medical study.
“Interactions between the developing microbiome and maturing immune system in early life are critical for establishing conditions that are beneficial to both the individual and the microbiota that inhabit each of us,” they said.
“We know that preterm babies and those born by caesarean section often have higher levels of certain health conditions later in life, so anything we can do to minimise that gap in the days after birth could have enormous short- and long-term benefits.”
“We would love to determine whether there are patterns of microbiome colonisation that correlate with future health or diseases,” they said.
First step toward new microbiome therapies
Associate Professor Sam Forster from Hudson Institute claims this research could be the first step toward finding new microbiome-based therapies.
“We now have access to technologies that allow us to investigate interactions between the respiratory microbiome and host immune system,” A/Prof Forster said. “This could unlock the potential for microbiome-based therapeutics, offering hope of avoiding a range of problems later in life.”
“For example, preterm babies already receive probiotics in the days after birth; what we’ve shown here is that there is scope for potential new and better interventions with enormous long-term benefits.”
Hudson Institute communications
t: + 61 3 8572 2761